PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings • Assumptions PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights • Key buying criteria PART 05: Overview: Vaginal atrophy • Symptoms • Causes • Pathophysiology • Diagnosis • Treatment • Epidemiology PART 06: Branded drug profiles • Activella • Enjuvia • Estrace • Femring • Premarin • Osphena • Vagifem PART 07: Market landscape • Market overview • Market size and forecast PART 08: Market segmentation by drug class • Topical estrogen • Systemic estrogen PART 09: Geographical segmentation • Global PVA drugs market by geographical segmentation 2015-2020 • PVA drugs market in Americas • PVA drugs market in US • PVA drugs market in EMEA • PVA drugs market in Europe • PVA drugs market in APAC • PVA drugs market in Japan PART 10: Market drivers • Significant unmet medical needs • Favorable healthcare reforms in US • Increase in awareness of PVA • Cost-effective OTC drugs PART 11: Impact of drivers PART 12: Market challenges • Patent expiry of branded products • Low diagnosis rates • Poor patient adherence • Side effects of drugs PART 13: Impact of drivers and challenges PART 14: Market trends • Paradigm shift to non-estrogenic therapies • Increased R&D • Patient assistance programs • Strategic alliances PART 15: Vendor landscape • Competitive scenario • Market share analysis 2015 • Pfizer • Allergan • Shionogi • Novo Nordisk • Teva Pharmaceutical • Other prominent vendors PART 16: Appendix • List of abbreviations PART 17: Explore Technavio   List of Exhibits Exhibit 01: Product offerings Exhibit 02: Key buying criteria for PVA drugs Exhibit 03: Symptoms of PVA Exhibit 04: Exhibit 05: Percentage of major vaginal atrophy symptoms in postmenopausal women Exhibit 06: Causes of PVA Exhibit 07: Effects of estrogen deficiency Exhibit 08: Treatment for PVA Exhibit 09: Some hormonal treatments for PVA Exhibit 10: Top concerns associated with OTC lubricants or moisturizers for PVA Exhibit 11: Top concerns about use of vaginal estrogen for PVA Exhibit 12: Prevalence of vaginal atrophy symptoms in postmenopausal women by country 2014 Exhibit 13: Global PVA drugs market 2015-2020 ($ billions) Exhibit 14: Five forces analysis Exhibit 15: Global PVA drugs market segmentation by drug class Exhibit 16: Global PVA drugs market share by drug class Exhibit 17: Preference for oral or vaginal ROA by age 2014 Exhibit 18: Global PVA drugs market by geography 2015 Exhibit 19: Global PVA drugs market revenue by geography 2015-2020 ($ millions) Exhibit 20: Global PVA drugs market: YoY revenue and growth based on geography 2015-2020 ($ millions) Exhibit 21: PVA drugs market in Americas 2015-2020 ($ billions) Exhibit 22: PVA drugs market in Americas by country 2015 Exhibit 23: PVA drugs market in US 2015-2020 ($ billions) Exhibit 24: Share of PVA drugs in US by drug class 2015 Exhibit 25: PVA drugs market in EMEA 2015-2020 ($ millions) Exhibit 26: PVA drugs market in EMEA by region 2015 Exhibit 27: PVA drugs market in Europe 2015-2020 ($ millions) Exhibit 28: Share of PVA drugs in Europe by drug class 2015 Exhibit 29: PVA drugs market in APAC 2015-2020 ($ millions) Exhibit 30: PVA drugs market in APAC by country 2015 Exhibit 31: PVA drugs market in Japan 2015-2020 ($ millions) Exhibit 32: Share of PVA drugs in Japan by drug class 2015 Exhibit 33: Specific OTC treatments for vaginal atrophy Exhibit 34: Impact of drivers Exhibit 35: Impact of drivers and challenges Exhibit 36: Global PVA drugs market share analysis 2015 Exhibit 37: Market share analysis of top vendors 2015 Exhibit 38: Timeline and history of Premarin Exhibit 39: Pfizer: YoY revenue and growth rate of Premarin 2013-2015 ($ billions) Exhibit 40: Pfizer: Geographical segmentation of Premarin 2015 Exhibit 41: Pfizer: Key takeaways Exhibit 42: Allergan: YoY revenue and growth rate of Estrace 2013-2015 ($ millions) Exhibit 43: Allergan: Key takeaways Exhibit 44: YoY revenue comparison of Osphena 2013 and 2014 ($ millions) Exhibit 45: Shionogi: Key takeaways Exhibit 46: Novo Nordisk: Key takeaways Exhibit 47: Timeline for Enjuvia Exhibit 48: Teva Pharmaceutical: Key takeaways

Pfizer Inc., Allergan Inc., Shionogi & Co. Ltd., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd, Bayer, Bionovo, EndoCeutics, Foamix Pharmaceuticals, Ligand Pharmaceuticals, Pantarhei Bioscience, Pep-Tonic Medical, TherapeuticsMD, Upsher-Smith Laboratories.